Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819589 | 0.84 | DPP4 (0.55) | DPP4DPP8DPP7DPP9P2RX7 | |
| SCHEMBL5646141 | 0.73 | DPP4 (0.47) | DPP4DPP8DPP7DPP9P2RX7 | |
| SCHEMBL4716733 | 0.71 | DPP4 (0.47) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL5935850 | 0.69 | DPP4 (0.48) | DPP4DPP8DPP7P2RX7 | |
| SCHEMBL25279581 | 0.69 | ESR2 (0.39) | — | |
| SCHEMBL24657050 | 0.69 | UCHL1 (0.34) | — | |
| SCHEMBL24654887 | 0.69 | UCHL1 (0.34) | — | |
| SCHEMBL34469320 | 0.69 | ELANE (0.39) | — | |
| SCHEMBL29324502 | 0.69 | UCHL1 (0.34) | — | |
| SCHEMBL24654886 | 0.69 | UCHL1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.